Market Cap 1.75B
Revenue (ttm) 232.28M
Net Income (ttm) -6.39M
EPS (ttm) N/A
PE Ratio 74.06
Forward PE 41.23
Profit Margin -2.75%
Debt to Equity Ratio 0.00
Volume 2,869,800
Avg Vol 1,718,340
Day's Range N/A - N/A
Shares Out 131.46M
Stochastic %K 68%
Beta 1.32
Analysts Strong Sell
Price Target $24.25

Latest News on DVAX

Dynavax Advances Board Refreshment Program

Jan 27, 2025, 6:00 AM EST - 26 days ago

Dynavax Advances Board Refreshment Program


Dynavax Announces $200 Million Share Repurchase Program

Nov 7, 2024, 4:01 PM EST - 3 months ago

Dynavax Announces $200 Million Share Repurchase Program


Dynavax Adopts Limited-Duration Stockholder Rights Plan

Oct 29, 2024, 8:30 AM EDT - 4 months ago

Dynavax Adopts Limited-Duration Stockholder Rights Plan


3 'Repeatable' Biotech Trades

Sep 25, 2024, 12:46 PM EDT - 5 months ago

3 'Repeatable' Biotech Trades

FOLD GSK NTLA XBI


Dynavax to Present at Upcoming Investor Conferences

May 28, 2024, 4:18 PM EDT - 9 months ago

Dynavax to Present at Upcoming Investor Conferences


Dynavax Technologies: Still A Believer

Mar 24, 2024, 7:39 AM EDT - 11 months ago

Dynavax Technologies: Still A Believer


Dynavax Technologies: Still A Solid Pick For 2024

Jan 2, 2024, 1:53 PM EST - 1 year ago

Dynavax Technologies: Still A Solid Pick For 2024